Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori

Autor:	Tzung-Shiun, Wu, Ping-I, Hsu, Chao-Hung, Kuo, Huang-Ming, Hu, I-Chen, Wu, Sophie S W, Wang, Yen-Hsu, Chen, Deng-Chyang, Wu, Wei-Wen, Su, Fu-Chen, Kuo
Rok vydání:	2017
Předmět:	Adult Male Helicobacter pylori Amoxicillin Proton Pump Inhibitors Levofloxacin Middle Aged Anti-Bacterial Agents Helicobacter Infections Medication Adherence Disk Diffusion Antimicrobial Tests Rabeprazole Drug Resistance Bacterial Gastroscopy Retreatment Organometallic Compounds Humans Drug Therapy Combination Female Antacids Prospective Studies Aged
Zdroj:	Journal of digestive diseases. 18(9)
ISSN:	1751-2980
Popis:	This was a prospective study aiming to investigate whether levofloxacin plus bismuth-based quadruple therapy was more effective than levofloxacin-based triple therapy after failed first-line eradication therapies for Helicobacter pylori (H. pylori) infection.Sixty-seven patients infected with H. pylori were randomly assigned to two groups; the levofloxacin plus bismuth-based quadruple therapy group (RBAL [n = 33]; rabeprazole 20 mg twice daily, bismuth subcitrate 120 mg four times daily, amoxicillin 1 g twice daily and levofloxacin 500 mg once daily, for 10 days) and the levofloxacin-based triple therapy group (RAL [n = 34]; rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily and levofloxacin 500 mg once daily, for 10 days). Endoscopy was performed 4-8 weeks after H. pylori eradication to assess treatment response. We followed up patient response and compliance and checked their resistance to antibiotics.Intention-to-treat analysis revealed that both groups had similar eradication rates (RBAL vs RAL: 84.8% [95% confidence interval {CI} 72.6-97.1%] vs 67.6% [95% CI 51.9-83.4%], P = 0.0987). No significant differences in compliance or adverse events were found (P = 0.9829 and 0.0720). Epsilometer test showed that most eradication failure cases were levofloxacin-resistant.Adding bismuth subcitrate to levofloxacin-based triple therapy was not more effective than not doing so, but no further side effects were noted. Both eradication therapies were equally safe and patients had the same tolerance to both regimens. Resistance rate to levofloxacin may be important when choosing second-line therapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::29ffb289d4eb2bade278a67cb48336a8 https://pubmed.ncbi.nlm.nih.gov/28644575 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.